NCT07521722 · NOT YET RECRUITING
DIV-AD BARCELONA: Alzheimer's Blood-Based Biomakers for a Diverse Community
This observational study is measuring Alzheimer's-related proteins in blood samples from cognitively healthy adults aged 50 to 75 in Barcelona. Researchers want to know whether those blood marker levels differ across ethnic groups and whether factors like income or education affect the results. There is no drug or intervention involved. The phase is unspecified, meaning this is likely a straightforward observational or feasibility study rather than a clinical drug trial.
You may qualify if
- Cognitively Unimpaired individuals aged between 50 and 75 years at the time of signing the informed consent
- Individuals interested in participating, able to follow study procedures, and who understand that all the tests are carried out in a research context.
- Explicit desire to participate in the tests and procedures of the study, including: collection of study variables, cognitive and neurologic assessment, blood sampling.
- Signing the informed consent, agreeing not to receive the research results that will not be of no clinical interest for the participant.
You're excluded if
- Cognitive decline defined by CDR>0.
- Individuals with cognitive complaints and who have sought for medical help for cognitive impairment at any time in their life
- Patients with relevant medical illnesses that may significantly interfere with the interpretation of results. This includes auditory and visual perception disorders, active oncological disease under treatment (localized tumors are excluded) and any condition that, in the investigator's opinion, may interfere with the correct performance/interpretation of the study procedures and/or with future permanence in the study.
- Major psychiatric disorders (according to the DSM-V manual) or diseases that affect cognitive abilities (major depressive episode, bipolar disorder, schizophrenia, etc).
- Acquired brain damage: history of head trauma with macroscopic parenchymal or non-axial lesion, large-vessel ischemic or hemorrhagic stroke, brain tumours and any other etiologies that can cause acquired brain damage (i.e., chemotherapy or brain radiotherapy).
- Parkinson's disease, epilepsy under treatment and with frequent seizures (> 1/month) in the last year, multiple sclerosis or other neurodegenerative diseases.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-04-13